BioSyent Inc. (RX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

welcome to the Bioscience Inc Q2 and first half 2025 results presentation my name is Rene Gorham and I'm the president and CEO of the company before I dive into the presentation I just want to draw your attention to our forward-looking statements disclaimer and I'm likely to make some during this presentation so this presentation is being recorded and In the second half of August, I wanted to welcome you, if you're a first-timer, to this presentation. We do this on a quarterly basis. You'll find the link in our press release if that's not how you got here in the first place. And also, we often put out a commentary if there's a significant event in the company. We also do a similar thing. We'll typically link it in a press release if it's always required. If you are a shareholder or a frequent viewer, welcome back. We're recording this presentation, as I said, in the second half of August. So we not only have we had a good start to the year, which I'm going to speak about in a couple of moments, but we really are halfway through the third quarter and the business across the board on a Canadian pharma, international pharma and legacy basis is performing well. So that momentum that we've built up through the first six months of the year has carried on and you see good momentum as we work towards the latter part of the third quarter. So let's dive into revenue for the quarter. On a total company basis, revenue was just over $10 million, representing 14% growth to the year ago. Overall, Canadian Pharma had a record quarter. Our EBITDA was just under $2.8 million, 35% growth to the year ago, and on a NEAD basis, once again, also strong, over $2 million at 28% growth to the year ago. Of note here are the margins that we're earning on EBITDA and NEAT. You'll see 27% EBITDA m...